secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001628280-26-028892
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved
--------------------------------------------------------------------------------

- Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.
- 2026 revenue guidance raised to $950-$1,050M (from prior range).
- FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026; NCCN preferred regimen.
- Cash and investments $515.4M at March 31, 2026. Expect return to profitability in Q2 2026.
- ROSELLA trial results published in The Lancet; BELLA, SYNERGY, MONARCH, DAZALS trials ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/0001628280-26-028892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer